Biotech catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
Windows longer than 90 days are part of TrialScanner, so this list covers the next 90 days.
November 2026
- Primary completion Nov 19, 2026Sponsor estimatePhase 2NCT07230860A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic DermatitisJanssen Research & Development, LLC · Dermatitis, AtopicActive, not recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 20, 2026Sponsor estimatePhase 2NCT05851443A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe AsthmaIncyte Corporation · Moderate to Severe AsthmaActive, not recruitingINCYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 20, 2026Sponsor estimatePhase 2NCT06577090Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs PlaceboSkye Bioscience, Inc. · ObesityActive, not recruitingSKYELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 24, 2026Sponsor estimatePhase 2NCT06616974A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)Tectonic Therapeutic · Pulmonary HypertensionActive, not recruitingTECXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 1/Phase 2NCT02704858Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated GliomaNeonc Technologies, Inc. · Glioblastoma MultiformeActive, not recruitingNTHILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 1/Phase 2NCT03989414A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination...Celgene · Multiple MyelomaActive, not recruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 1/Phase 2NCT05094336A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)Amgen · Advanced MTAP-null Solid TumorsActive, not recruitingAMGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 1/Phase 2NCT05095727A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)ModernaTX, Inc. · Glycogen Storage DiseaseActive, not recruitingMRNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 2NCT05339126RNS System LGS Feasibility StudyNeuroPace · EpilepsyActive, not recruitingNPCELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 2NCT07081633Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular CarcinomaAstraZeneca · Hepatocellular CarcinomaActive, not recruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 2NCT07656727A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular...BioAge Labs, Inc. · Obesity and Cardiovascular RiskActive, not recruitingBIOALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
December 2026
- Primary completion Dec 2026Sponsor estimatePhase 2NCT03604198Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing SyndromeCorcept Therapeutics · Cushing SyndromeActive, not recruitingCORTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2/Phase 3NCT04442022A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse...Karyopharm Therapeutics Inc · Relapsed/Refractory Diffuse Large B-cell LymphomaActive, not recruitingKPTIQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2/Phase 3NCT04704921Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMDAbbVie · AMDActive, not recruitingABBVLeadRGNXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1/Phase 2NCT05262023A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants...Denali Therapeutics Inc. · Frontotemporal DementiaActive, not recruitingDNLILeadTAKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT05396885Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)Kite, A Gilead Company · Multiple MyelomaActive, not recruitingGILDLeadACLXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1/Phase 2NCT05546268Study of Oral MRT-2359 in Selected Cancer PatientsMonte Rosa Therapeutics, Inc · NSCLCActive, not recruitingGLUELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1/Phase 2NCT05664243A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination...In8bio Inc. · GlioblastomaActive, not recruitingINABLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1/Phase 2NCT05885464A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell...Beam Therapeutics Inc. · Lymphoblastic LymphomaActive, not recruitingBEAMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1/Phase 2NCT05925608Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem CellsBioCardia, Inc. · Heart Failure, SystolicActive, not recruitingBCDALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT06107413Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV)...AbbVie · Unresectable Metastatic Colorectal CancerActive, not recruitingABBVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1/Phase 2NCT06109181Gene Therapy for ACM Due to a PKP2 Pathogenic VariantLexeo Therapeutics · Arrhythmogenic CardiomyopathyActive, not recruitingLXEOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2/Phase 3NCT06132893A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset EpilepsyBiohaven Therapeutics Ltd. · Focal EpilepsyActive, not recruitingBHVNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT06246110A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLCEikon Therapeutics · NSCLCActive, not recruitingEIKNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT06298955Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal HemoglobinuriaOmeros Corporation · Paroxysmal Nocturnal HemoglobinuriaActive, not recruitingOMERLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 50 more in this window; the full list is part of TrialScanner.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.